Dr. Schuchter Discusses the Treatment of Melanoma

Lynn M. Schuchter, MD
Published: Wednesday, Jul 03, 2013

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Schuchter notes that it is important to determine the BRAF status of every patient with advanced melanoma. If a patient has a large disease burden, a physician should start treatment with targeted therapy to achieve a fast response. Conversely, if a patient is not in need of immediate treatment, immunotherapy should be considered.

Schuchter says that it is truly remarkable that chemotherapy is no longer considered in the first or second line. Data presented at this year's ASCO meeting enhances the knowledge of the impact of new immunotherapies.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Schuchter notes that it is important to determine the BRAF status of every patient with advanced melanoma. If a patient has a large disease burden, a physician should start treatment with targeted therapy to achieve a fast response. Conversely, if a patient is not in need of immediate treatment, immunotherapy should be considered.

Schuchter says that it is truly remarkable that chemotherapy is no longer considered in the first or second line. Data presented at this year's ASCO meeting enhances the knowledge of the impact of new immunotherapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x